PDS Biotechnology (PDSB) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 9, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about PDSB filings

Are insiders buying or selling PDS Biotechnology Corp (PDSB) stock?

Neither. PDS Biotechnology Corp (PDSB) insiders filed no open-market purchases or sales in the 90 days to Nov 9, 2026, according to SEC Form 4 filings.

Which members of Congress have traded PDSB recently?

None. No member of Congress disclosed a PDSB trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this PDSB smart-money data?

This summary uses filings available on Nov 9, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

No recent filings found.

7 funds hold a position.

Questions about PDSB filings

Are insiders buying or selling PDS Biotechnology Corp (PDSB) stock?

Neither. PDS Biotechnology Corp (PDSB) insiders filed no open-market purchases or sales in the 90 days to Nov 9, 2026, according to SEC Form 4 filings.

Which members of Congress have traded PDSB recently?

None. No member of Congress disclosed a PDSB trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this PDSB smart-money data?

Checking federal contract awards

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 12, 2026

Earnings came in 38.5% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 12, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.18-38.46% miss

-$0.13 expected

Revenue

$0.00

SEC filing · No operating revenue

Next report

Estimated report: Nov 12, 2026, in 3 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Jun 30, 2026Reported Aug 12, 2026	-$0.18est. -$0.13	-38.46%miss	$0.00SEC filing	No year-ago quarter
Mar 31, 2026Reported May 13, 2026	-$0.13est. -$0.14	+7.14%beat	Not on file	Not on file
Dec 31, 2025Reported Mar 30, 2026	-$0.14est. -$0.18	+20.77%beat	Not on file	Not on file
Sep 30, 2025Reported Nov 13, 2025	-$0.19est. -$0.20	+5.00%beat	Not on file	Not on file
Jun 30, 2025Reported Aug 13, 2025	-$0.21est. -$0.23	+8.70%beat	Not on file	Not on file
Mar 31, 2025Reported May 14, 2025	-$0.21est. -$0.25	+16.00%beat	Not on file	Not on file
Dec 31, 2024Reported Mar 27, 2025	-$0.21est. -$0.28	+23.64%beat	Not on file	Not on file
Sep 30, 2024Reported Nov 14, 2024	-$0.29est. -$0.28	-3.57%miss	Not on file	Not on file

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $1.28
High: $1.29
Low: $1.13
Prev close: $1.30
52-wk high: $1.79
52-wk low: $0.20
Mkt cap: $129.2M
ROE: -544.0%
Beta: 1.13
P/B: 3.5x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $129M

Valuation

P/B3.47

Quality

Operating margin0.0%
ROE-544.0%
ROA-70.6%

Growth

Beta1.13

Technicals

Price structure

This stock is in a strong uptrend.

Trend

Strong uptrend

80 / 100

RSI 14

51balanced

20D volatility

217%annualized

52-week range

$1.17

$0.20$1.79

20D support

$0.90recent floor

20D resistance

$1.79recent ceiling

Returns

5D -24.5%20D +14.7%60D +383.5%

Price vs moving averages

SMA20 -9.5%SMA50 +31.8%SMA200 +39.8%

Volume pace

0.19xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Jun 30, 2026Aug 12, 2026

-$0.18est. -$0.13

-38.46%

$0.00SEC filing

No year-ago quarter

Mar 31, 2026May 13, 2026

-$0.13est. -$0.14

+7.14%

Not on file

Dec 31, 2025Mar 30, 2026

-$0.14est. -$0.18

+20.77%

Not on file

Sep 30, 2025Nov 13, 2025

-$0.19est. -$0.20

+5.00%

Not on file

Jun 30, 2025Aug 13, 2025

-$0.21est. -$0.23

+8.70%

Not on file

Mar 31, 2025May 14, 2025

-$0.21est. -$0.25

+16.00%

Not on file

Dec 31, 2024Mar 27, 2025

-$0.21est. -$0.28

+23.64%

Not on file

Sep 30, 2024Nov 14, 2024

-$0.29est. -$0.28

-3.57%

Not on file

PDS Biotechnology Corp

Smart money at a glance

What do analysts expect?

Questions about PDSB filings

Questions about PDSB filings

How top traders are positioned

Unlock everything for $29/month

Earnings came in 38.5% below what analysts expected.

Estimated report: Nov 12, 2026, in 3 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

PDS Biotechnology Corp

Smart money at a glance

What do analysts expect?

Questions about PDSB filings

Questions about PDSB filings

How top traders are positioned

Unlock everything for $29/month

Earnings came in 38.5% below what analysts expected.

Estimated report: Nov 12, 2026, in 3 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

PDS Biotechnology Corp

Overview

Questions about PDSB filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

PDS Biotechnology Corp

Overview

Questions about PDSB filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.